Alkylating agents
IMRT + Chemotherapy + Stem Cell Transplant for Leukemia
This trial is giving IMRT with chemotherapy to patients with relapsed or refractory ALL or AML before a donor stem cell transplant. The aim is to find out the side effects of this treatment and the best dose of IMRT to give, as well as how well the IMRT and chemotherapy work in treating patients.
Anti-metabolites
Fludarabine +2 More for Graft Failure
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (\<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an allogeneic SCT from an HLA-Identical or non-identical family donor or unrelated donors, with fludarabine (150mg/m2) and TBI (400cGy), with post-transplantation immunosuppression utilizing tacrolimus and MMF. B. To evaluate the incidence of transplant related mortality. Minor Objectives A. To evaluate the incidence of acute and chronic GVHD after second allogeneic HCT utilizing Tac/MMF with peripheral blood stem cells from matched or mis-matched allogeneic donors. B. To evaluate disease responses and survival after second allogeneic SCT. C. To evaluate the need for DLI after second transplant for either disease control or persistent mixed chimerism.
Procedure
Kidney + Stem Cell Transplant for Immune Tolerance
This trial is testing whether blood stem cells, when injected after kidney transplantation and combined with lymphoid irradiation, will change the immune system such that immunosuppressive drugs can be completely withdrawn.
Alkylating agents
Cyclophosphamide 30 +4 More for Osteopetrosis
Reduced intensity conditioning followed by allogeneic stem cell transplantation will result in mixed/complete donor chimerism and potentially alter the natural history and outcome of patients with non-malignant diseases.
Popular Filters
Trials for Mantle Cell Lymphoma Patients
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Radioimmunotherapy
Zevalin +1 More for Non-Hodgkin's Lymphoma
The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.
Trials for Diffuse Large B-Cell Lymphoma Patients
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Radioimmunotherapy
Zevalin +1 More for Non-Hodgkin's Lymphoma
The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.
Monoclonal Antibodies
Zevalin + Stem Cell Transplant for Non-Hodgkin Lymphoma
This trial is testing whether giving ibritumomab tiuxetan before a donor peripheral blood stem cell transplant helps treat patients with relapsed or refractory non-Hodgkin lymphoma.
Trials for HLA Positive Patients
Alkylating agents
Stem Cell Transplant for Autoimmune Neurological Diseases
This trial tests a combination of strong chemotherapy and an immune-suppressing medicine followed by a stem cell transplant. It targets patients with autoimmune neurological diseases that haven't improved with other treatments. The treatment aims to weaken the immune system to stop it from attacking the nervous system and then helps the body recover by making new blood cells. High-dose chemotherapy followed by a stem cell transplant has been shown to improve various autoimmune diseases.
CAR T-cell Therapy
WT1-specific T Cells for Multiple Myeloma
This trial tests the safety of special white blood cells from a donor that are trained to attack a protein made by multiple myeloma cancer cells. The goal is to see if these cells can effectively kill the cancer cells and understand their effects on patients.
Stem Cell Therapy
CD34+ Stem Cell Selection for Bone Marrow Failure Syndromes
This trial uses a special machine to filter out harmful cells from donor blood to make stem cell transplants safer for young patients with non-cancerous diseases. By removing specific cells, it aims to prevent a serious immune reaction.
Phase 3 Trials
Alkylating agents
Combination Chemotherapy for Ewing's Sarcoma
This trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.
Alkylating agents
Combination Chemotherapy + Stem Cell Transplant/Radiation for Retinoblastoma
This trial is studying side effects and how well giving a combination of chemotherapy and either an autologous stem cell transplant or radiation therapy works in treating young patients with extraocular retinoblastoma.
Alkylating agents
Chemotherapy + Stem Cell Transplant for Brain Cancer
This trial is studying two different chemotherapy combinations to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma.
Trials With No Placebo
Behavioral Intervention
Positive Psychology for Bone Marrow Transplant Survivors
"This trial is studying how a positive psychology program called PATH can help improve anxiety, depression, and quality of life in people who have had a stem cell transplant, compared to standard care."
Alkylating agents
Chemotherapy + Stem Cell Transplant for Breast Cancer
This trial is testing a combination of strong cancer drugs, stem cell replacement, surgery, and radiation in patients with severe stage IIIB breast cancer. The goal is to kill cancer cells, help the body recover, remove the tumor, and eliminate any remaining cancer cells.
View More Related Trials
Frequently Asked Questions
Introduction to stem cell transplant
What are the top hospitals conducting stem cell transplant research?
When it comes to cutting-edge research in stem cell transplant, several top hospitals are leading the way. Located in Duarte, California, the City of Hope Medical Center stands out with ten active clinical trials focused on this groundbreaking treatment method. Stem cell transplantation offers hope for patients with a range of conditions by replacing damaged or diseased cells with healthy ones derived from their own bodies or donated sources. Meanwhile, across the country in New York City, Memorial Sloan Kettering Cancer Center is also making strides in this field with nine ongoing trials dedicated to stem cell transplants. Their efforts aim to improve outcomes and expand the potential applications of this transformative therapy.
In Houston, Texas, M D Anderson Cancer Center is at the forefront too; they have eight active clinical trials exploring various aspects of stem cell transplantations. This innovative technique has been proven effective for treating blood cancers like leukemia and lymphoma as well as certain genetic disorders and immune deficiencies.
Notably contributing to this progress is Washington University School of Medicine located in Saint Louis which currently has eight ongoing initiatives aimed towards understanding better how we can benefit from these treatments further.Held alongside these impressive institutions' work lies another central institution based back at Duarte itself: City of Hope Comprehensive Cancer Center; here they boast an array seven actively performed experiments exploring benefits associated with applying stem-cell-transplant methods on different patient groups suffering from a varietyof diseases.
The pioneering work conducted by these esteemed medical centers signifies significant advancements not just within specific regions but throughout national healthcare systems as well — offering renewed hope for countless individuals seeking life-saving solutions through stem cell transplantation.
Which are the best cities for stem cell transplant clinical trials?
When it comes to stem cell transplant clinical trials, several cities have emerged as leaders in research and development. Chicago, Illinois, and Boston, Massachusetts both offer 22 active trials exploring innovative treatments such as pharmacological studies, autologous hematopoietic stem cell transplantation, and interleukin-2 interventions. New york City follows closely behind with 19 ongoing trials focused on methotrexate treatment and gene-modified T cells targeted therapies. Additionally, Duarte, California showcases 18 active trials investigating multi-peptide CMV-modified vaccinia Ankara vaccines and allogeneic hematopoietic stem cell transplantation. Finally, Seattle, Washington offers 17 trials centered around autologous and allogeneic hematopoietic stem cell transplantation. These cities serve as hubs of cutting-edge research in the field of stem cell transplants for those seeking advanced treatment options.
Which are the top treatments for stem cell transplant being explored in clinical trials?
The field of stem cell transplant is witnessing exciting advancements through ongoing clinical trials. Leading the charge are three standout treatments, each showing great promise in their respective studies:
- Daratumumab: Currently being explored in six active trials for stem cell transplant.
- Belantamab mafodotin: Showing potential in four ongoing clinical trials.
- Lenalidomide: Under investigation in three active studies.
These treatments have captured the attention of researchers due to their encouraging results and potential to revolutionize the field of stem cell transplantation.
What are the most recent clinical trials for stem cell transplant?
The field of stem cell transplant is advancing rapidly, with recent clinical trials offering new insights and potential treatments. One noteworthy trial is Arm A, a Phase 3 study that explores the effectiveness of stem cell transplantation. Additionally, another Phase 2 trial investigates the benefits of CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplantation using a Busulfan/Melphalan/Fludarabine Regimen. Patients with various conditions such as AML, ALL, MDS, MPN, CML, NHL, HD, CLL requiring AHSCT are also partaking in a Phase 2 trial to assess the outcomes of their stem cell transplants. Another significant study focuses on allogeneic hematopoietic stem cell transplantation for patients seeking this form of treatment. The development and evaluation of fostamatinib for use in conjunction with stem cell transplant rounds out these latest trials—an exciting prospect for enhancing patient care and outcomes in this field.
What stem cell transplant clinical trials were recently completed?
Recently, several stem cell transplant clinical trials have reached completion, bringing hope to patients seeking innovative treatments. In March 2021, the University of California San Francisco concluded their trial investigating the effectiveness of autologous stem cell transplantation for multiple myeloma patients. Similarly, in January 2021, a study led by Memorial Sloan Kettering Cancer Center examined allogeneic stem cell transplantation as a potential therapy for acute myeloid leukemia and related disorders. These significant milestones highlight advancements in utilizing stem cells to combat these challenging diseases and pave the way for future breakthroughs.